#fda

3 articles tagged #fda.

Ready to compare providers? Take the 2-minute match quiz or see the cheapest GLP-1 options.

#2026 4#503a 1#503b 2#FDA 1#alternatives 1#ban 1#before-and-after 1#beginners 2#brand-name 3#bridge-program 1#cagrilintide 1#cagrisema 1#comparison 2#compounded 8#compounded-semaglutide 1#compounded-tirzepatide 1#compounding-ban 1#copay 1#cost 13#coupon 1#coverage 1#diabetes 1#diet 1#dosage 1#eli-lilly 3#enforcement 1#enrollment 1#fact-check 1#fda 3#fda-approval 1#flat-rate 1#foundayo 7#framework 1#glp-1-patches 1#glucose-monitors 1#guide 1#hhs 1#hims 1#how-to-get 1#injectable 7#injection 1#insulin-resistance 1#insurance 11#ivy-rx 1#ivyrx 1#legality 1#liraglutide 1#medicaid 1#medicare 5#mounjaro 6#news 2#novo-nordisk 2#oral-glp1 6#oral-semaglutide 1#orforglipron 4#ozempic 7#pcos 1#pill 1#pipeline 1#policy 1#prior-authorization 2#regulation 2#results 1#rfk 1#ro 1#safety 3#savings-card 1#schedule 1#semaglutide 19#shortage 1#side-effects 9#supplements 1#surmount 2#surmount-5 1#telehealth-enforcement 1#telehealth-review 1#timeline 1#tirzepatide 18#type-2-diabetes 1#warning-letters 1#wegovy 16#wegovy-hd 1#wegovy-pill 3#weight-loss 26#without-insurance 1#zepbound 17
Editorial lifestyle photograph of official documents on an oak desk illustrating a regulatory proposal
NewsNews & PipelineMay 8, 2026• 7 min read

FDA Proposes Permanent 503B Compounding Ban for Semaglutide, Tirzepatide & Liraglutide

Verified May 8, 2026, Updated June 29, 2026: On April 30, FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulk list, forever, not just during shortage enforcement. Public comment period extended to July 30, 2026 (from June 29 via Federal Register 2026-12937, published June 26, 2026). If finalized, no 503B pharmacy could bulk-compound these GLP-1 drugs in the future, even if a new shortage is declared. 503A patient-specific compounding under medical-necessity remains unaffected.

Editorial lifestyle still-life accompanying a guide to Zepbound side effects and management
GuideSide Effects & SafetyApril 20, 2026• 10 min read

Zepbound Side Effects (2026): Nausea 29%, Diarrhea 23%, Vomiting 13%, Full Guide with SURMOUNT Trial Data

Verified April 2026: Zepbound (tirzepatide) side effects from the SURMOUNT clinical trials, nausea affects 24-29% of patients (vs 8% placebo), diarrhea 19-23%, vomiting 8-13%. Only 4.3% discontinued at the highest dose. GI symptoms peak during dose escalation and resolve within 4-8 weeks for most patients. Full breakdown by dose, timeline, management strategies, and when to call your doctor.

Featured Partners

Four affiliate partners we feature, we may earn a commission.

TrimRx

7.8/10
$149/mo·Compounded
Visit TrimRxReview

Gala

7.2/10
$149/mo·Brand & Compounded
Visit GalaReview

Embody

7.3/10
$149/mo·Compounded
Visit EmbodyReview

SkinnyRx

7.3/10
$199/mo·Compounded
Visit SkinnyRxReview

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. The objective ranking (by methodology score) and full methodology are at glp1picks.com/best.